Research programme: antisense oligonucleotide therapeutics - Cajal Neuroscience/Creyon Bio/
Latest Information Update: 20 May 2024
At a glance
- Originator Cajal Neuroscience; Creyon Bio
- Class Antisense oligonucleotides
- Mechanism of Action Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurodegenerative disorders